The IBDX®panel is a non-invasive blood test based on serological biomarkers. This panel enables
physician to quickly and easily complete the diagnosis of Inflammatory Bowel Disease (IBD) vs non-IBD. This
panel also differentiates between the two main subtypes of IBD; Chron's disease and Ulcerative Colitis. IBDX®
your disease progression, your likelihood for Chron's disease complications, and the need for abdominal
surgery. IBDX® was fully validated on pediatric populations and can provide a valuable and
non-invasive tool for children.
For more detail see >>
Serological markers are distinctive indicators of biological progressions. Certain antibodies are found to be present in the blood of people with different diseases. Our tests recognize and measure the presence of these antibodies in your blood, enabling us to identify whether or not you have a certain disease.
The tests significantly reduce the amount of time and number of procedures required for your physician to accurately diagnosis these diseases. Diagnosis frequently involves a biopsy (removal of a small amount of the intestinal lining).
Serological tests offer physicians another tool and are not an invasive procedure. They just require a simple blood draw and are relatively inexpensive compared to other diagnostic tools available.
The IBDX® panel significantly reduces the amount of time and number of procedures you will have to undergo until diagnosis confirmation (usually by biopsy). The IBDX® panel has a high degree of sensitivity (low false negatives) while maintaining a high specificity (low false positives) for the IBD differential diagnosis between Chron's disease and Ulcerative Colitis.
The IBDX® panel makes an earlier diagnosis possible; without the current invasive procedures. Early diagnosis can enable you and your doctor to begin an earlier and more accurate treatment protocol. Additionally, early diagnosis of IBD can help prevent some serious complications, including colon removal in 25% to 40% of UC patients. The IBDX® panel is able to correctly identify ~80% of the patients that have Crohn’s disease. This is higher than other available tests.
Crohn’s disease does not have a constant appearance. It varies according to locations, behaviors, severities, and activities. It is considered a multifactorial disease and as a result requires a combination of several serological markers (IBDX® panel) for a full diagnosis. Our panel of serological markers can also assist your doctor in identifying the exact type of Crohn’s disease for a given patient. This panel predicts severity and complications of CD (strictures, fistulas and the need for surgery) and can be used at the onset of disease.
If you are suspected to have IBD or need more information about your disease, your physician may refer you to do the IBDX® blood test in your closest local laboratory. Once your physician receives the results and verifies the diagnosis he may initiate the proper treatment to ease the symptoms and control the outbreaks.
We are committed to continuously discovering and developing advanced gastroenterology tests that will improve the quality of life for you, your family, and millions of other patients.